

NLM Citation: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Telaprevir. [Updated 2023 Apr 15]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



Telaprevir

Revised: April 15, 2023.

CASRN: 402957-28-2

Drug Levels and Effects

Summary of Use during Lactation

Telaprevir is no longer marketed in the United States and has not been studied in nursing mothers. Because it must be used with ribavirin and peginterferon alfa, it is not considered a good choice during breastfeeding. When it was marketed, the manufacturer recommended that mothers taking telaprevir not breastfeed their infants.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Hepatitis C) Interferon Alfa, Interferon Alfacon-1

Substance Identification

Substance Name

Telaprevir

CAS Registry Number

402957-28-2

Drug Class

Breast Feeding

Lactation

Milk, Human

Antiviral Agents